SEARCH

SEARCH BY CITATION

References

  • 1
    Calderón MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011;127:3038.
  • 2
    Burks AW, Calderón MA, Casale T, Cox L, Demoly P, Jutel M et al. Update on allergy immunotherapy: American academy of allergy, asthma and immunology/european academy of allergy and clinical immunology/ PRACTALL consensus report. J Allergy Clin Immunol 2013. doi: 10.1016/j.jaci.2013.01.049.
  • 3
    Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:15721573.
  • 4
    Freeman J. Further observations on the treatment of hay-fever by hypodermic inoculation of pollen vaccine. Lancet 1911;2:814817.
  • 5
    Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317324.
  • 6
    Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102:558562.
  • 7
    Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8160.
  • 8
    Bousquet PJ, Brozek J, Bachert C, Bieber T, Bonini S, Burney P et al. The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. Allergy 2009;64:17371745.
  • 9
    Bousquet PJ, Calderón MA, Demoly P, Larenas D, Passalacqua G, Bachert C et al. The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol 2011;127:4956.
  • 10
    Bousquet J, Schünemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012;130:10491062.
  • 11
    Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta EEAACI, Immunotherapy Task Force. Standards for practical allergen-specific immunotherapy. Allergy 2006;61(Suppl 82):120.
  • 12
    Calderon M, Cardona V, Demoly P, EAACI 100 Years of Immunotherapy Experts Panel. One hundred years of allergen immunotherapy European academy of allergy and clinical immunology celebration: review of unanswered questions. Allergy 2012;67:462476.
  • 13
    Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127:S1S55.
  • 14
    Committee for Medicinal Products for Human Use. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006. London. European Medicines Agency. Pre-authorisation evaluation of medicines for human use. 20 November 2008. Available at http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003605.pdf. Last accessed 20 March 2013
  • 15
    Allergic rhinitis: clinical development programs for drug products. Guidance for Industry. Beltsville, MD, April 2000. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available at www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071293.pdf. Last accessed 20 March 2013.
  • 16
    Guidance for reviewers. Potency limits for standardized dust mite and grass allergen vaccines: a revised protocol. Beltsville, MD, November 2000. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available at http://www.fda.gov/OHRMS/DOCKETS/98fr/000218gd.pdf. Last accessed 20 March 2013.
  • 17
    Zhang L, Götz M, Hofmann S, Greiner J. Immunogenic targets for specific immunotherapy in multiple myeloma. Clin Dev Immunol. 2012;2012:820394.
  • 18
    Esch RE. Specific immunotherapy in the U.S.A.: general concept and recent initiatives. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2003;94:1723.
  • 19
    Bieber T, Simon HU. Allergen-specific immunotherapy: current concepts and future directions. Allergy 2011;66:709712.
  • 20
    Ring J, Gutermuth J. 100 years of hyposensitization: history of allergen-specific immunotherapy (ASIT). Allergy 2011;66:713724.
  • 21
    Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier B, Lockey R et al. A revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of World Allergy Organization. J 7Allergy Clin Immunol 2004;113:832836.